ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 36.9 | 25.2 | 22.4 |
| Total income | 36.9 | 25.2 | 22.4 |
| Profit before exceptional items & tax | 1.1 | 1.2 | 0.2 |
| Profit before tax | 1.1 | 1.2 | 0.2 |
| Net profit | 1.2 | 0.9 | 0.1 |
| Operating margin | 3.0% | 4.8% | 0.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1100.00% |
|---|---|
| Net profit, quarter on quarter | +33.30% |
| Revenue, year on year | +64.70% |
BSE results filing, NSE: TRIMURTHI. Figures extracted from the filing.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹71.50
- Market cap
- ₹126.0 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 27.0×Sector 66.2×
- Promoter holding
- 54.29%+3.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals reported no deviation in its July 2026 fund raise utilisation for the September quarter. This periodic statement records no new business event.
Novelix Pharmaceuticals Q2 FY27 Results: Net Profit ₹1.6 Cr, Up 220.0% YoY
Novelix Pharmaceuticals Ltd reported revenue from operations of ₹44.7 Cr (+22.8% YoY) and net profit of ₹1.6 Cr (+220.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.6 Cr · +220.0% YoY
Novelix Pharmaceuticals Board Meeting Date
Novelix Pharmaceuticals has given prior intimation of a board meeting on 11 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window stays closed until forty-eight hours after the meeting.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals held its 32nd Annual General Meeting on 30th September, 2026, transacting ordinary and special business items via e-voting and video conferencing.